Cancer vaccine - Sanofi Genzyme

Drug Profile

Cancer vaccine - Sanofi Genzyme

Alternative Names: Breast cancer vaccine - Sanofi Genzyme; Ovarian cancer vaccine - Sanofi Genzyme

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator Genzyme Corporation
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Breast cancer; Malignant melanoma; Renal cancer

Most Recent Events

  • 06 Jul 2004 Data presented at the 40th Annual Meeting of the American Society of Clinical Oncology (ASCO-2004) have been added to the adverse events and Cancer therapeutic trials sections
  • 06 Jul 2004 Genzyme has completed enrolment in a phase I/II (electrofusion) trial for renal cancer in the USA
  • 29 Jul 2003 Genzyme General, Genzyme Biosurgery and Genzyme Molecular Oncology are now called Genzyme Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top